share_log

三爱健康集团(01889)拟2200万港元出售Zentrogene Bioscience Laboratory Limited 59%股权

Sanai Health Group (01889) plans to sell 59% of Zentrogene Bioscience Laboratory Limited's shares for HK$22 million

Zhitong Finance ·  Apr 17 10:18

Sanai Health Group (01889) announced that on April 17, 2024, the company is a wholly-owned subsidiary of Sanai International Investment...

Zhitong Finance App News, Sanai Health Group (01889) announced that on April 17, 2024, the company's wholly-owned subsidiary Sanai International Investment Co., Ltd. plans to sell 59% of the entire issued share capital of Zentrogene Bioscience Laboratory Limited to Merit Investment Holding Limited at a cost of HK$22 million, to be settled in cash.

According to reports, the target company is an indirect wholly-owned subsidiary of the company, which is mainly engaged in providing (including) genetic testing and molecular biological diagnosis services. The target company operates a laboratory with the required license in Hong Kong to provide services such as non-invasive prenatal diagnosis, cancer genetic screening, DNA testing and paternity testing.

After reviewing the target company's performance and strategic positioning, the board of directors believes that the partial divestment will enable management to reallocate energy and resources to the core pharmaceutical business. The divestment will also provide the Group with additional working capital.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment